Profile data is unavailable for this security.
About the company
Allergy Therapeutics plc is a United Kingdom-based international commercial biotechnology company. The Company is focused on the treatment and diagnosis of allergic disorders, including aluminum free immunotherapies that have the potential to cure disease. It sells proprietary and third-party products from its subsidiaries in nine European countries and via distribution agreements in an additional 10 countries. It sells both injectable and sublingual (oral) allergen-specific immunotherapies. Its pipeline of products in clinical development includes vaccines for grass, tree, house dust mite and peanut. Its therapies are traded under various brand names depending on the market, such as Pollinex Quattro, Polligoid and TA Graser Top. Its commercial products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics and Acarovac Plus. Its pipeline candidates include Grass MATA MPL, Birch MATA MPL, Ragweed MATA MPL, Trees MATA MPL, and VLP Peanut.
- Revenue in GBP (TTM)55.04m
- Net income in GBP-40.13m
- Incorporated2004
- Employees584.00
- LocationAllergy Therapeutics PLCDominion WayWORTHING BN14 8SAUnited KingdomGBR
- Phone+44 190 384 4700
- Fax+44 190 384 4726
- Websitehttps://www.allergytherapeutics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kexing Biopharm Co Ltd | 160.80m | 13.32m | 644.54m | 947.00 | 48.03 | 3.49 | -- | 4.01 | 0.6288 | 0.6288 | 7.47 | 8.65 | 0.473 | 4.20 | 2.90 | 1,601,171.00 | 3.82 | -0.1893 | 5.31 | -0.2413 | 63.12 | 74.57 | 8.07 | -0.3956 | 1.38 | 63.54 | 0.4489 | -- | 11.75 | 3.39 | 116.54 | -27.74 | 11.90 | -- |
| ChengDu Sheng Nuo Biotec Co Ltd | 67.69m | 12.73m | 645.24m | 1.38k | 50.77 | 5.90 | -- | 9.53 | 0.7615 | 0.7615 | 4.09 | 6.56 | 0.3714 | 0.973 | 4.28 | 462,238.30 | 6.98 | 6.05 | 10.10 | 7.75 | 55.34 | 66.00 | 18.80 | 14.91 | 0.9008 | 14.11 | 0.3862 | 26.83 | 4.84 | 6.90 | -28.88 | 0.7741 | 51.66 | -- |
| Mochida Pharmaceutical Co Ltd | 536.93m | 30.81m | 651.21m | 1.51k | 20.59 | 0.9621 | 14.46 | 1.21 | 181.16 | 181.16 | 3,156.95 | 3,876.77 | 0.6427 | 1.67 | 3.02 | 74,214,190.00 | 3.69 | 4.50 | 4.47 | 5.44 | 48.43 | 52.49 | 5.74 | 6.87 | 2.85 | -- | 0.0678 | 43.01 | 2.21 | 0.6516 | 25.03 | 4.34 | 1.98 | 0.00 |
| Pacira Biosciences Inc | 525.14m | 15.71m | 655.52m | 790.00 | 46.68 | 1.29 | 7.96 | 1.25 | 0.4664 | 0.4664 | 15.70 | 16.93 | 0.5085 | 1.11 | 6.64 | 907,330.40 | 1.52 | 1.87 | 1.78 | 2.22 | 79.17 | 73.06 | 2.99 | 4.84 | 3.78 | -- | 0.3413 | 0.00 | 3.85 | 10.73 | -337.30 | -- | 0.9219 | -- |
| Allergy Therapeutics plc | 55.04m | -40.13m | 663.28m | 584.00 | -- | -- | -- | 12.05 | -0.0084 | -0.0084 | 0.0116 | -0.0059 | 0.8219 | 1.93 | 9.29 | 94,253.42 | -59.92 | -35.76 | -91.26 | -48.31 | 53.23 | 62.40 | -72.91 | -40.59 | 0.7635 | -2.35 | 1.88 | -- | -0.2808 | -6.78 | -3.91 | -- | 6.08 | -- |
| Marksans Pharma Ltd | 226.80m | 29.15m | 666.35m | 1.35k | 22.84 | -- | 17.95 | 2.94 | 7.96 | 7.96 | 61.92 | -- | -- | -- | -- | 20,780,450.00 | -- | 14.15 | -- | 17.41 | 56.77 | 51.56 | 12.90 | 14.58 | -- | 20.42 | -- | 7.77 | 20.46 | 18.25 | 21.32 | 26.60 | 23.73 | 51.57 |
| Procter & Gamble Health Ltd | 109.10m | 23.74m | 670.00m | 1.33k | 28.24 | -- | 26.18 | 6.14 | 176.64 | 176.64 | 811.45 | -- | -- | -- | -- | 10,169,760.00 | -- | -- | -- | -- | 72.49 | -- | 21.76 | -- | -- | 806.81 | -- | -- | -- | -- | -- | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| JPMorgan Chase Bank, NA (Investment Management)as of 01 Dec 2025 | 129.00m | 2.10% |
| West Yorkshire Pension Fundas of 01 Dec 2025 | 13.88m | 0.23% |
| IG Markets Ltd.as of 01 Dec 2025 | 8.20m | 0.13% |
| Hargreaves Lansdown Fund Managers Ltd.as of 01 Dec 2025 | 6.91m | 0.11% |
| Santander Asset Management SA SGIICas of 01 Dec 2025 | 4.42m | 0.07% |
| HSBC Global Asset Management (UK) Ltd.as of 01 Dec 2025 | 3.93m | 0.06% |
| Raiffeisen Kapitalanlage-Gesellschaft mbHas of 01 Dec 2025 | 2.67m | 0.04% |
| Banque Pictet & Cie SAas of 01 Dec 2025 | 2.53m | 0.04% |
| iDealing.com Ltd.as of 01 Dec 2025 | 1.45m | 0.02% |
| Bank Julius B�r & Co. AGas of 01 Dec 2025 | 1.39m | 0.02% |
